Table 1. Clinicopathological Features of PTC Patients With Different BRAF Mutation Statusa.
| Variables | Total | BRAF V600E Mutation | ||
|---|---|---|---|---|
| Positive | Negative | P Value | ||
| Age, years | 40.9 ± 13.7 | 38.8 ± 13.1 | 36.7 ± 12.4 | 0.527 |
| Male, n (%) | 15 (25.0) | 8 (33.3) | 7 (19.4) | 0.180 |
| Female, n (%) | 45 (75.0) | 16 (66.7) | 29 (80.6) | |
| Tumor size (cm) | 1.58 ± 1.20 | 1.98 ± 0.82 | 1.31 ± 1.35 | 0.039b |
| Extracapsular invasion | 14 (23.7) | 6 (25) | 8 (22.9) | 0.544 |
| Lymph node metastasis | 27 (49.1) | 15 (62.5) | 12 (34.3) | 0.030b |
| Lymphovascular invasion | 8 (13.6) | 4 (16.7) | 4 (11.4) | 0.418 |
| Tumor stage (AJCC), n (%) | ||||
| I | 46 (79.3) | 17 (70.8) | 29 (85.3) | 0.153 |
| II | 3 (5.2) | 1 (4.2) | 2 (5.9) | |
| III | 7 (12.1) | 5 (20.8) | 2 (5.9) | |
| IVA | 2 (3.4) | 1 (4.2) | 1 (2.9) | |
Abbreviations: PTC, papillary thyroid carcinoma; AJCC, American Joint Committee on Cancer.
a Data are presented as n(%), except age and tumor size as mean ± SD
b P value < 0.05